Johnson & Johnson COVID-19 vaccine Johnson & Johnson temporarily halts making COVID-19 vaccine: Report
Johnson & Johnson has paused late last year the production in its only plant making usable batches of COVID-19 vaccine in the Dutch city of Leiden, where it is now making an experimental but potentially more profitable vaccine to protect against an unrelated virus, according to a New York Times report.
According to the report, the halt is temporary and the Leiden will start making the Covid-19 shots after a few months.
J&J reported a COVID shot sale of $2.39 billion for 2021, lower than its own target of $2.5 billion, and has millions of doses of its COVID-19 vaccine in inventory.
For the year 2022, it has forecast a sale of Rs $3.5 billion in sales of its COVID-19 vaccine in 2022, a 46 percent jump.
The temporary halt in the production of the Covid-19 vaccine in the Leiden plant could cut down the supply of the J&J vaccine by some hundred million doses, the NYT report said, citing a source aware of the decision.
The report said that the company has hired some other facilities for the production of the vaccine but either they are not yet ready or haven't received the regulatory nod to make the shot.
